Vaxart, Inc. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
Vaxart, Inc. (VXRT) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $12.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2026-08-06
- Vaxart, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-06-30 was $2.88M, a 70.00% decline year-over-year.
- Vaxart, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-03-31 was $10.00M, a 51.69% decline year-over-year.
- Vaxart, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-12-31 was $6.00M, a 76.92% decline year-over-year.
- Vaxart, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-09-30 was $3.70M, a 48.00% increase year-over-year.
- Vaxart, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2023 was $73.20M, a 65.61% increase from fiscal 2022.
- Vaxart, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2022 was $44.20M, a 675.44% increase from fiscal 2021.
- Vaxart, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2021 was $5.70M.
- Vaxart, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2020 was $0.00.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.88M derived: 10-Q 6 month − S-1 3 month · filed 2026-08-06 | $12.88M 10-Q · filed 2026-08-06 | $18.88M derived: sum of 3 quarters · filed 2026-08-06 | $22.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $10.00M S-1 · filed 2026-05-08 | $16.00M derived: sum of 2 quarters · filed 2026-05-08 | $19.70M derived: sum of 3 quarters · filed 2026-05-08 | $29.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $6.00M derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08 | $9.70M derived: sum of 2 quarters · filed 2026-05-08 | $19.30M derived: sum of 3 quarters · filed 2026-08-06 | $40.00M S-1 · filed 2026-05-08 |
| 2025-09-30 | $3.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $13.30M derived: sum of 2 quarters · filed 2026-08-06 | $34.00M 10-Q · filed 2025-11-13 | $60.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $9.60M derived: 10-Q 6 month − S-1 3 month · filed 2026-08-06 | $30.30M 10-Q · filed 2026-08-06 | $56.30M derived: sum of 3 quarters · filed 2026-08-06 | $58.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $20.70M S-1 · filed 2026-05-08 | $46.70M derived: sum of 2 quarters · filed 2026-05-08 | $49.20M derived: sum of 3 quarters · filed 2026-05-08 | $59.20M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $26.00M derived: S-1 12 month − 10-Q 9 month · filed 2026-05-08 | $28.50M derived: sum of 2 quarters · filed 2026-05-08 | $38.50M derived: sum of 3 quarters · filed 2026-05-08 | $43.50M S-1 · filed 2026-05-08 |
| 2024-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $12.50M derived: sum of 2 quarters · filed 2025-11-13 | $17.50M 10-Q · filed 2025-11-13 | $32.50M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $15.00M 10-Q · filed 2025-08-13 | $30.00M derived: sum of 3 quarters · filed 2025-08-13 | $40.00M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $5.00M 10-Q · filed 2025-05-13 | $20.00M derived: sum of 2 quarters · filed 2025-05-13 | $30.00M derived: sum of 3 quarters · filed 2025-05-13 | $51.50M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $25.00M derived: sum of 2 quarters · filed 2025-03-20 | $46.50M derived: sum of 3 quarters · filed 2025-03-20 | $73.20M 10-K · filed 2025-03-20 |
| 2023-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $31.50M derived: sum of 2 quarters · filed 2024-11-13 | $58.20M 10-Q · filed 2024-11-13 | $79.70M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $21.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $48.20M 10-Q · filed 2024-08-08 | $69.70M derived: sum of 3 quarters · filed 2024-08-08 | $76.40M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $26.70M 10-Q · filed 2024-05-13 | $48.20M derived: sum of 2 quarters · filed 2024-05-13 | $54.90M derived: sum of 3 quarters · filed 2024-05-13 | $57.30M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $21.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $28.20M derived: sum of 2 quarters · filed 2024-03-14 | $30.60M derived: sum of 3 quarters · filed 2024-03-14 | $44.20M 10-K · filed 2024-03-14 |
| 2022-09-30 | $6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $9.10M derived: sum of 2 quarters · filed 2023-11-02 | $22.70M 10-Q · filed 2023-11-02 | $23.90M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $16.00M 10-Q · filed 2023-08-03 | $17.20M derived: sum of 3 quarters · filed 2023-08-03 | $20.50M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $13.60M 10-Q · filed 2023-05-04 | $14.80M derived: sum of 2 quarters · filed 2023-05-04 | $18.10M derived: sum of 3 quarters · filed 2023-05-04 | $19.30M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $4.50M derived: sum of 2 quarters · filed 2023-03-15 | $5.70M derived: sum of 3 quarters · filed 2023-03-15 | $5.70M 10-K · filed 2023-03-15 |
| 2021-09-30 | $3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.50M derived: sum of 2 quarters · filed 2022-11-09 | $4.50M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.20M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 derived: sum of 3 quarters · filed 2021-02-25 | $1.99M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $1.99M 10-Q · filed 2019-11-12 | $16.49M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.99M 10-Q · filed 2019-08-08 | $16.49M derived: sum of 3 quarters · filed 2019-08-08 | $29.89M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $1.99M 10-Q · filed 2019-05-09 | $16.49M derived: sum of 2 quarters · filed 2019-05-09 | $29.89M derived: sum of 3 quarters · filed 2019-05-09 | $32.29M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $14.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-06 | $27.90M 10-Q · filed 2018-02-06 | $30.30M derived: sum of 3 quarters · filed 2018-08-10 | $10.58M 10-K · filed 2019-02-06 |
| 2017-09-30 | $13.40M 10-Q · filed 2017-11-07 | $15.80M derived: sum of 2 quarters · filed 2018-08-10 | $8.08M 10-Q · filed 2018-11-13 | $29.16M derived: sum of 4 quarters · filed 2018-08-10 |
| 2017-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $6.06M 10-Q · filed 2018-08-10 | $15.76M derived: sum of 3 quarters · filed 2018-08-10 | $34.70M 10-K · filed 2017-09-01 |
| 2017-03-31 | $3.67M 10-Q · filed 2018-05-15 | $13.37M derived: sum of 2 quarters · filed 2018-05-15 | $20.30M 10-Q · filed 2017-05-08 | $21.46M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $9.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-06 | $16.60M 10-Q · filed 2018-02-06 | $17.80M derived: sum of 3 quarters · filed 2018-02-06 | $23.70M derived: sum of 4 quarters · filed 2018-02-06 |
| 2016-09-30 | $6.90M 10-Q · filed 2017-11-07 | $8.10M derived: sum of 2 quarters · filed 2017-11-07 | $14.00M derived: sum of 3 quarters · filed 2017-11-07 | $22.00M derived: sum of 4 quarters · filed 2017-11-07 |
| 2016-06-30 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-01 | $7.10M derived: sum of 2 quarters · filed 2017-09-01 | $15.10M derived: sum of 3 quarters · filed 2017-09-01 | $16.10M 10-K · filed 2017-09-01 |
| 2016-03-31 | $5.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-08 | $13.90M derived: sum of 2 quarters · filed 2017-05-08 | $14.90M 10-Q · filed 2017-05-08 | |
| 2015-12-31 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-06 | $9.00M 10-Q · filed 2017-02-06 | ||
| 2015-09-30 | $1.00M 10-Q · filed 2016-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |